Influence of CYP2C19*18 and CYP2C19*19 alleles on omeprazole 5-hydroxylation: In vitro functional analysis of recombinant enzymes expressed in Saccharomyces cerevisiae

Basic and Clinical Pharmacology and Toxicology

Volumn 102, Issue 4, 2008, Pages 388-393

  Hanioka, Nobumitsu ^a   Tsuneto, Yumi ^a   Saito, Yoshiro ^b   Maekawa, Keiko ^b   Sawada, Jun Ichi ^b   Narimatsu, Shizuo ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CYTOCHROME P450 2C19; GLYCINE; HISTIDINE; LANSOPRAZOLE; OMEPRAZOLE; RECOMBINANT ENZYME; SERINE; VALINE; CYP2C19 PROTEIN, HUMAN; MIXED FUNCTION OXIDASE; PROTON PUMP INHIBITOR; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE;

ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG METABOLISM; DRUG PROTEIN BINDING; GENETIC VARIABILITY; HYDROXYLATION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SACCHAROMYCES CEREVISIAE; YEAST CELL; ENZYME SPECIFICITY; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; HUMAN; KINETICS; METABOLISM; MICROSOME; MOLECULAR CLONING;

SACCHAROMYCES CEREVISIAE;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; CLONING, MOLECULAR; HUMANS; HYDROXYLATION; KINETICS; MICROSOMES; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; POLYMORPHISM, GENETIC; PROTON PUMP INHIBITORS; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE; SUBSTRATE SPECIFICITY;

EID: 40849102618     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2008.00222.x     Document Type: Article

References (37)

1. Wilde MI, McTavish D. Omeprazole: an update of its pharmacology and therapeutic use in acid-related disorders. Drugs 1994 48 : 91 132.
2. Smallwood RA, Berlin RG, Castagnoli N, Festen HP, Hawkey CJ, Lam SK et al. Safety of acid-suppressing drugs. Dig Dis Sci 1995 40 : 63S 80S.
3. 14C]omeprazole in humans. Drug Metab Dispos 1989 17 : 69 76.
4. Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Tassaneeyakul W, Meyer UA et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993 36 : 521 30.
5. Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T, Ishizaki T. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther 1993 266 : 52 9.
6. Andersson T, Miners JO, Veronese ME, Birkett DJ. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 1994 37 : 597 604.
7. Äbelö A, Andersson TB, Antonsson M, Naudot AK, Skånberg I, Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000 28 : 966 72.
8. Li XQ, Weidolf L, Simonsson R, Andersson TB. Enantiomer/enantiomer interactions between the S- and R-isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4. J Pharmacol Exp Ther 2005 315 : 777 87.
9. de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994 46 : 594 8.
10. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994 269 : 15419 22.
11. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001 52 : 349 55.
12. Kita T, Tanigawara Y, Aoyama N, Hohda T, Saijoh Y, Komada F et al. CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability. Pharm Res 2001 18 : 615 21.
13. Ieiri I, Kubota T, Urae A, Kimura M, Wada Y, Mamiya K et al. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 1996 59 : 647 53.
14. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998 129 : 1027 230.
15. Furuta T, Ohashi K, Kobayashi K, Iida I, Yoshida H, Shirai N et al. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin Pharmacol Ther 1999 66 : 265 74.
16. Wedlund PJ. The CYP2C19 enzyme polymorphism. Pharmacology 2000 61 : 174 83.
17. Ferguson RJ, De Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998 284 : 356 61.
18. Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamou S, Bouchardy C et al. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 1998 8 : 129 35.
19. Ibeanu GC, Goldstein JA, Meyer U, Benhamou S, Bouchardy C, Dayer P et al. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther 1998 286 : 1490 5.
20. Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, Brosen K, Benhamou S et al. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant S-mephenytoin. J Pharmacol Exp Ther 1999 290 : 635 40.
21. Blaisdell J, Mohrenweiser H, Jackson J, Ferguson S, Coulter S, Chanas B et al. Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 2002 12 : 703 11.
22. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006 79 : 103 13.
23. Fukushima-Uesaka H, Saito Y, Maekawa K, Ozawa S, Hasegawa R, Kajio H et al. Genetic variations and haplotypes of CYP2C19 in a Japanese population. Drug Metab Pharmacokinet 2005 20 : 300 7.
24. Hanioka N, Tsuneto Y, Saito Y, Sumada T, Maekawa K, Saito K et al. Functional characterization of two novel CYP2C19 variants (CYP2C19*18 and CYP2C19*19) found in a Japanese population. Xenobiotica 2007 37 : 342 55.
25. Sakaki T, Akiyoshi-Shibata M, Yabusaki Y, Ohkawa H. Organella-targeted expression of rat liver cytochrome P450c27 in yeast. Genetically engineered alteration of mitochondrial P450 into a microsomal form creates a novel functional electron transport chain. J Biol Chem 1992 267 : 16497 502.
26. Romanos MA, Scorer CA, Clare JJ. Foreign gene expression in yeast: a review. Yeast 1992 8 : 423 88.
27. Wan J, Imaoka S, Chow T, Hiroi T, Yabusaki Y, Funae Y. Expression of four rat CYP2D isoforms in Saccharomyces cerevisiae and their catalytic specificity. Arch Biochem Biophys 1997 348 : 383 90.
28. Hichiya H, Takemi C, Tsuzuki D, Yamamoto S, Asaoka K, Suzuki S et al. Complementary DNA cloning and characterization of cytochrome P450 2D29 from Japanese monkey liver. Biochem Pharmacol 2002 64 : 1101 10.
29. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951 193 : 265 75.
30. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 1964 239 : 2370 8.
31. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970 227 : 680 5.
32. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979 76 : 4350 4.
33. Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 1997 283 : 434 42.
34. Hofmann U, Schwab M, Treiber G, Klotz U. Sensitive quantification of omeprazole and its metabolites in human plasma by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2006 83 : 85 90.
35. Shimizu M, Uno T, Niioka T, Yaui-Furukori N, Takahata T, Sugawara K et al. Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography: application to pharmacokinetic study in relation to CYP2C19 genotypes. J Chromatogr B Analyt Technol Biomed Life Sci 2006 832 : 241 8.
36. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994 33 : 1743 52.
37. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997 29 : 413 580.